Show simple item record

dc.contributor.authorAzizzadeh, F
dc.contributor.authorMahmoodi, J
dc.contributor.authorSadigh-Eteghad, S
dc.contributor.authorFarajdokht, F
dc.contributor.authorMohaddes, G
dc.date.accessioned2018-08-26T08:56:18Z
dc.date.available2018-08-26T08:56:18Z
dc.date.issued2017
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/54425
dc.description.abstractBackground: Ghrelin is a peptide with attenuating effect on inflammatory pain. Both anti- and pro-inflammatory mediators have a role in the nociception and development of pain and hyperalgesia. IL-10 and TGF-? are anti-inflammatory cytokines and inhibit the expression of pro-inflammatory cytokines related to peripheral and central inflammatory pain. In this study, the effects of i.p. injection of ghrelin on the early and the late phases of pain, as well as serum levels of IL-10 and TGF-?, as anti-inflammatory cytokines, were investigated in formalin-induced pain in male rats. Methods: Adult male Wistar rats (n=48) were randomly divided into six groups: control, formalin+saline, ghrelin (40, 80, and 160 ?g/kg), and morphine. Ghrelin was administered i.p. 30 min before inducing pain by formalin. Pain induced by intraplantar (i.pl.) injection of 50 آµl formalin 5%, and pain behavior was studied for 60 min. Serum IL-10 and TGF-? levels were assessed by ELISA method. Results: The findings of the present study showed that ghrelin with high doses (80 and 160 ?g/kg) significantly reduced pain intensity in both the early and the late phases of pain. The serum levels of cytokines, IL-10, and TGF-?1 showed a significant elevation with ghrelin at the dose of 160 ?g/kg. Conclusion: Ghrelin is effective in reducing the intensity of both the early and the late phases of inflammatory pain. It seems that ghrelin exerts its analgesic effects in part by increasing the serum levels of anti-inflammatory cytokines. é 2017, Pasteur Institute of Iran. All rights reserved.
dc.language.isoEnglish
dc.relation.ispartofIranian Biomedical Journal
dc.subjectformaldehyde
dc.subjectghrelin
dc.subjectinterleukin 10
dc.subjectmorphine
dc.subjecttransforming growth factor beta
dc.subjectanalgesic agent
dc.subjectghrelin
dc.subjectinterleukin 10
dc.subjectmorphine
dc.subjecttransforming growth factor beta
dc.subjectadult
dc.subjectanalgesic activity
dc.subjectanimal behavior
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectantiinflammatory activity
dc.subjectArticle
dc.subjectcontrolled study
dc.subjectdose response
dc.subjectdrug dose comparison
dc.subjectenzyme linked immunosorbent assay
dc.subjectinflammatory pain
dc.subjectmale
dc.subjectnonhuman
dc.subjectpain intensity
dc.subjectprotein blood level
dc.subjectrat
dc.subjectanimal
dc.subjectblood
dc.subjectcomplication
dc.subjectdisease model
dc.subjectdrug effect
dc.subjectinflammation
dc.subjectnociception
dc.subjectpain
dc.subjectWistar rat
dc.subjectAnalgesics
dc.subjectAnimals
dc.subjectDisease Models, Animal
dc.subjectGhrelin
dc.subjectInflammation
dc.subjectInterleukin-10
dc.subjectMale
dc.subjectMorphine
dc.subjectNociception
dc.subjectPain
dc.subjectRats, Wistar
dc.subjectTransforming Growth Factor beta
dc.titleGhrelin exerts analgesic effects through modulation of IL-10 and TGF-? levels in a rat model of inflammatory pain
dc.typeArticle
dc.citation.volume21
dc.citation.issue2
dc.citation.spage114
dc.citation.epage119
dc.citation.indexScopus
dc.identifier.DOIhttps://doi.org/10.18869/acadpub.ibj.21.2.114


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record